NAYA Biosciences, Inc
INVO Fertility, Inc., a life science portfolio company, develops clinical stage assets to treat patients with fertility, oncology, and autoimmune diseases. The company operates in two divisions, NAYA Women's Health and NAYA Therapeutics. Its lead product includes NY-303, a GPC3-targeted FLEX-NK bispecific antibody that is in Phase I/II clinical trials for hepatocellular carcinoma, as well as soli… Read more
NAYA Biosciences, Inc (NAYA) - Total Assets
Latest total assets as of December 2024: $46.45 Million USD
Based on the latest financial reports, NAYA Biosciences, Inc (NAYA) holds total assets worth $46.45 Million USD as of December 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
NAYA Biosciences, Inc - Total Assets Trend (2007–2024)
This chart illustrates how NAYA Biosciences, Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
NAYA Biosciences, Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
NAYA Biosciences, Inc's total assets of $46.45 Million consist of 2.8% current assets and 97.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 1.6% |
| Accounts Receivable | $174.88K | 0.4% |
| Inventory | $219.76K | 0.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $18.10 Million | 39.0% |
| Goodwill | $23.54 Million | 50.7% |
Asset Composition Trend (2007–2024)
This chart illustrates how NAYA Biosciences, Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: NAYA Biosciences, Inc's current assets represent 2.8% of total assets in 2024, a decrease from 6.0% in 2007.
- Cash Position: Cash and equivalents constituted 1.6% of total assets in 2024, up from 0.0% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 88.0% of total assets, an increase from 77.0% in 2007.
- Asset Diversification: The largest asset category is goodwill at 50.7% of total assets.
NAYA Biosciences, Inc Competitors by Total Assets
Key competitors of NAYA Biosciences, Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
NAYA Biosciences, Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - NAYA Biosciences, Inc generates 0.14x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - NAYA Biosciences, Inc is currently not profitable relative to its asset base.
NAYA Biosciences, Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.07 | 0.16 | 0.36 |
| Quick Ratio | 0.06 | 0.12 | 0.27 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-16.61 Million | $ -6.74 Million | $ -1.23 Million |
NAYA Biosciences, Inc - Advanced Valuation Insights
This section examines the relationship between NAYA Biosciences, Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.97 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | 151.0% |
| Total Assets | $46.45 Million |
| Market Capitalization | $2.48 Million USD |
Valuation Analysis
Below Book Valuation: The market values NAYA Biosciences, Inc's assets below their book value (0.05 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: NAYA Biosciences, Inc's assets grew by 151.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for NAYA Biosciences, Inc (2007–2024)
The table below shows the annual total assets of NAYA Biosciences, Inc from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $46.45 Million | +151.00% |
| 2023-12-31 | $18.51 Million | +398.84% |
| 2022-12-31 | $3.71 Million | -64.56% |
| 2021-12-31 | $10.47 Million | -4.39% |
| 2020-12-31 | $10.95 Million | +509.72% |
| 2019-12-31 | $1.80 Million | +130.98% |
| 2018-12-31 | $777.35K | +191.78% |
| 2017-12-31 | $266.41K | -6.92% |
| 2016-12-31 | $286.23K | -50.63% |
| 2015-12-31 | $579.79K | +220.33% |
| 2010-12-31 | $181.00K | -59.13% |
| 2009-12-31 | $442.84K | -41.85% |
| 2008-12-31 | $761.55K | +1265.48% |
| 2007-12-31 | $55.77K | -- |